Topics:

Doubling Imatinib Dose Ups CML Response Rates

Doubling Imatinib Dose Ups CML Response Rates

SAN DIEGO— Doubling the standard dose of imatinib mesylate (Gleevec) to 800
mg provided more complete cytogenetic responses (CCRs) more quickly with higher
rates of PCR (polymerase chain reaction) negativity than the standard dose (400
mg) in patients with previously untreated early-stage chronic myeloid leukemia
(CML).

The 400-mg dose was established as a standard dose based on somewhat
arbitrary criteria, said Jorge E. Cortes, MD, associate professor of medicine,
M.D. Anderson Cancer Center, in that phase I dose-finding trials of 25 to 1,000
mg showed a dose response without identifying a maximum tolerated dose.

Standard 400-mg doses in this population produce CCRs in the 70% to 80%
range in previously untreated patients and in the 40% to 60% range in patients
who have failed interferon therapy, Dr. Cortes said at the 45th Annual Meeting
of the American Society of Hematology (abstract 94). Molecular complete
remissions (undetectable levels of Bcr-Abl translocation by PCR), which
correlate with likelihood of disease progression, occur in only the 4% to 10%
range at this dose.

Initial experience with higher imatinib doses (600 mg and 800 mg) has been
promising in patients with cytogenetic resistance or relapse after 400 mg, Dr.
Cortes said.

To assess front-line therapy in patients with Philadelphia positive or
Bcr-Abl positive early chronic phase CML, the investigators gave oral daily
doses of imatinib 800 mg (400 mg twice daily) to 114 patients, and compared the
results with those of a prior study among 50 patients receiving the 400-mg
daily dose.

In both studies, nearly all patients had a complete hematologic response.
Overall, CCRs were reported in 78% of patients in the 400-mg study (median
follow-up, 31 months) and in 90% of patients in the 800-mg study (median
follow-up, 16 months, P = .01). By 3 months, 52% of patients receiving
800 mg had attained a CCR, compared with 36% in the standard-dose group (P
= .0005). By 6 months, the respective CCR rates were 82% and 52%.

The investigators also evaluated the quantitative PCR percentage ratio (%QPCR
= Bcr-Abl transcripts × 100/Abl) at different time points. After 6 months, 38%
of patients at the higher imatinib dose had reached values lower than 0.05%,
which represents about a 3 log reduction from baseline. By 12 months, 60% were
below this level.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.